NasdaqCM:TGTXBiotechs
Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release
TG Therapeutics (TGTX) is back in focus after publishing five year data from the open label extension of its Phase 3 ULTIMATE I and II BRIUMVI trials in relapsing multiple sclerosis, highlighting durable efficacy and safety.
See our latest analysis for TG Therapeutics.
The latest BRIUMVI data arrive as TG Therapeutics trades at US$29.23, with a 7 day share price return of 1.42% but a 30 day share price return decline of 4.38%. A 3 year total shareholder return of 72.96% contrasts with a 5...